Kenvue is guiding for $1.10 to $1.20 in 2024 earnings per share and 2% to 4% organic sales growth. If it achieves the ...

On Oct. 21, news broke that Starboard Value took a position in Kenvue. The firm thinks there is an opportunity to improve ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.

周四，Jefferies重申了对Kenvue Inc (NYSE:KVUE)的买入评级，目标价维持在$27.00。该公司的展望基于对公司护肤板块的转机预期，预计该板块将在2026年前反弹。分析强调，大规模的品牌改造通常需要时间才能见效。

Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...

(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Starboard Value, the activist investor pushing for changes at Pfizer, unveiled its goals for another healthcare company — ...

By Svea Herbst-Bayliss (Reuters) -Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its ...

Jeff Smith says pharma giant’s returns from recent efforts are ‘not adequate’ in speech at 13D activist investor conference ...

Starboard Value于2024年10月21日对成立不久的保健品销售商Kenvue进行战略投资，携手拓展个人护理产品市场。